Topic resource collection
Approved comparison material connected to this topic.
94 resourcesRead both sides
Copper Peptide (GHK-Cu) 340 Da VEGF/TGF-β upregulation, MMP activation, follicle remodelling High. Multiple RCTs showing 10–20% density increase at 24 weeks Requires lipophilic carrier; degrades in alkaline pH Gold standard for t…
Bremelanotide (PT-141) MC3R/MC4R agonist in hypothalamus. Increases dopamine signaling in arousal circuits Central desire and motivation FDA-approved; two Phase 3 RCTs showing 0.5–0.9 additional satisfying events/month vs placebo…
| Peptide | Mechanism of Action | Clinical Trial Evidence | Sleep Onset Latency Improvement | Slow-Wave Sleep Duration Increase | Typical Dosing Protocol | Professional Assessment ||—|—|—|—|—|—|| DSIP (Delta Sleep-Inducing Peptid…
Mechanism of Action Stimulates endogenous GH release from anterior pituitary via GHRH and ghrelin receptor agonism Direct delivery of synthetic GH into systemic circulation Peptides preserve pituitary function; HGH bypasses it en…
Mechanism of Action Stimulates endogenous pituitary GH secretion via GHRH and ghrelin receptor activation Direct exogenous replacement. Bypasses pituitary entirely Peptides preserve endogenous axis function; rhGH creates dependen…
Mechanism Stimulates endogenous production via HPG axis. Preserves testicular function and fertility Exogenous hormone delivery. Shuts down natural production via negative feedback Peptides preserve fertility and HPTA function; T…
BPC-157 VEGFR2 activation, angiogenesis promotion Mucosal repair, ulcer healing Preclinical strong, human limited Subcutaneous or intraperitoneal (oral bioavailability poor) Most promising for structural repair but human dosing p…
Different peptides target different stages of the rotator cuff healing cascade. This table compares the three most-researched compounds based on mechanism, evidence quality, and practical administration considerations. BPC-157 VE…
CJC-1295 + Ipamorelin GH secretagogue (pituitary stimulation) 100–200mcg each, combined 1–2× daily (preferably before bed and post-workout) Moderate. Multiple Phase 2 trials show 1–2kg fat loss over 12 weeks when paired with calo…
Thymalin T-regulatory cell enhancement, thymic function restoration Increases T-reg populations by 30–40% in autoimmune trials; addresses T-reg suppression seen in CIRS Randomised trials in autoimmune thyroiditis and RA (90+ pati…
The table below compares major peptide classes used in fat loss research protocols, organized by primary mechanism, typical dosing regimens, and documented efficacy. This comparison assumes proper reconstitution, sterile handling…
GHRP-2 Ghrelin receptor agonist. Stimulates endogenous GH release 100–200mcg 2–3x daily (fasted or pre-training) 3–4 weeks (IGF-1 elevation); 6–8 weeks (lean mass gains) Stimulates natural GH pulse without suppressing endogenous …
Hydrolyzed Collagen (oral) Fibroblast signaling via proline-hydroxyproline dipeptides; indirect collagen synthesis 10–15g daily oral Strong (15+ RCTs, meta-analyses available) Best-supported option for mild-to-moderate OA; requir…
A 2023 preclinical study from the Institute of Experimental Medicine in Saint Petersburg found that Selank. A synthetic derivative of tuftsin. Reduced anxiety-like behavior in rodent models by 40–60% through direct modulation of …
GHRP-2, GHRP-6, Ipamorelin GHS-R1a receptor agonism → endogenous GH release 8–15% increase in resting metabolic rate; 300–700% GH elevation within 30 min University of Copenhagen (2022), University of Virginia (2020) Most consist…
See the earlier comparison table in this article covering Cerebrolysin, Dihexa, P21, Thymalin, and Cartalax with columns for mechanism, dosing, storage, stability, and professional assessment. Researchers looking to explore high-…
Thymalin Restores thymic epithelial function; increases Treg differentiation Systemic lupus, Hashimoto's thyroiditis, rheumatoid arthritis, multiple sclerosis Subcutaneous or intramuscular 10–20mg twice weekly Multiple controlled…
P21 (CNTF fragment) NMDA receptor modulation, excitotoxicity reduction 40% infarct volume reduction in MCAO rodent stroke models (J Neurosci, 2015) Requires intranasal or intracerebroventricular delivery. Negligible systemic BBB …
GLP-1 Agonist (Semaglutide) GLP-1 receptor activation → slowed gastric emptying, extended satiety hormone elevation 14.9% at 68 weeks (STEP-1, 2.4mg weekly) Weekly subcutaneous injection 30–45% during titration (nausea, vomiting,…
Selank GABA-A receptor modulation, enkephalin metabolism inhibition Intranasal spray Strong (multiple RCTs in GAD, social anxiety) 30–60 minutes Most robust clinical data for anxiety-specific use; non-sedating; no tolerance devel…